August 15, 2026 06:49 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar | Bengal man arrested in Bengaluru over terror links, Afghanistan travel plan | Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe | From guns to glamour: Former women Maoists walk the ramp in Chhattisgarh
Johnson Baby Powder
Image Credit: wikipedia.org

Maharashtra FDA cancels Johnson & Johnson baby powder licence

| @indiablooms | Sep 18, 2022, at 05:06 am

Mumbai: The Maharashtra FDA has cancelled the baby talcum powder manufacturing licence of Johnson & Johnson, Mulund, after the department found it "Not Of Standard Quality".

The FDA said that the licence was cancelled after samples of the Johnson’s Baby Powder collected from Nashik and Pune failed quality checks and ordered the company to recall all its stocks from the markets.

These samples were declared by the FDA as ‘Not Of Standard Quality’ after they failed to comply with IS5339:2009 (Second Revision Amendment No. 3) Specification for Skin Powder for infants in the test pH.

In a statement, the FDA said: “The product Johnsons Baby Powder is popularly used in newborn babies. The sample declared 'Not of Standard' in pH and the use of the product may affect the health of the skin of the newborn babies.”

The firm "didn't accept the report" and challenged it in court for sending it to the Central Drugs Laboratory, the FDA said, according to media reports.

(With UNI inputs)

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.